ClinicalTrials.gg
Not yet recruitingNCT07599800PHNUpdated May 20, 2026

A Phase IIb/III Clinical Study to Evaluate the Efficacy and Safety of APC101 in Patients With Postherpetic Neuralgia.

A Phase 2/3 interventional study of APC101 and Control in PHN - Post-Herpetic Neuritis, sponsored by Andros Pharmaceuticals Co., Ltd.. Not yet recruiting at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-20.

Sponsored by Andros Pharmaceuticals Co., Ltd. · Phase 2/3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
333
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 27 studies in Neuritis with a site in United States — 5 open to participants now, 7 under way, 1 of them phase 3. Neuritis · United States.

Planned enrollment
2nd of 23
333 · median 30
Started
2026
with 1 other
Phase 2/3
Only one
of the 27
Registered
27th of 27
by date
Lead sponsor
1 of 27
Andros Pharmaceuticals Co., Ltd.

Among the 27 studies in Neuritis with a site in United States, this one is the 2nd largest by planned enrollment of the 23 interventional ones that give a count, is one of 2 that started in 2026, is the only one in phase 2/3, and was the 27th registered.

Neuritis

73 studies on the registry are indexed under Neuritis; 20 are open to participants now.

Browse Neuritis studies →

Open to participants now

5 of the 27 studies in Neuritis with a site in United States are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 14 Neuritis studies recruiting now, 11 (79%) set no upper age limit and 1 (7%) stops at 75 or younger; 2 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Neuritis with a site in United States, or all of them as a file.
02

Study summary

APC101 is developed to provide continuous lidocaine administration over 24 hours and is safe when administered to intact skin. Dispensing from a metered-dose spray pump, APC101 provides once or twice daily flexible dosing options that deliver medication without physically touching the afflicted allodynic skin site, resulting in very light, minimal contact with the painful, hypersensitive skin affected by PHN.

Read the detailed description

APC101 is a film-forming, sustained-release, and metered-dose topical spray. This investigational product (IP) is formulated with 5% by weight of lidocaine and several excipients. APC101 offers several unique properties or advantages over the first line topical treatment of lidocaine patches, including:

  • Can be applied to the area above the neck (face and head).
  • Contact-free: eliminating pain when apply to the skin of PHN patients.
  • Suitable to apply to uneven skin of PHN patient.
  • Less adverse reactions such as skin rash and redness at the application sites.
  • Less systemic absorption compared with patch, which shows safer profile.
  • Can be administered twice daily as needed.
  • The only prescription spray product providing pain relief for PHN with clinical evidence.

This is a Phase IIb/III, randomized, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of APC101 in patients with PHN.

03

Conditions studied

  • PHN - Post-Herpetic Neuritis

Browse trials for

Keywords

  • PHN
  • APC101
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Participants will be eligible for enrollment in the study only if they meet ALL the following inclusion criteria at the time of screening:

Inclusion criteria

Inclusion criteria:

  1. Males or females ≥ 18 years.
  2. Female of non- (i.e., 12 months or more of spontaneous amenorrhea without an alternative medical cause, bilateral oophorectomy at least 6 months prior to randomization, hysterectomy with bilateral oophorectomy at least 6 months prior to randomization,.
  3. Women of childbearing potential (WOCBP) must be confirmed to be not pregnant at Screening Visit.
  4. Males with sexual partners and females of childbearing potential must agree to use a highly effective method:

    • Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation:

      • Oral
      • Intravaginal
      • Transdermal
    • Progestogen-only hormonal contraception associated with inhibition of ovulation:

      • Oral
      • Injectable
      • Implantable
    • Intrauterine device (IUD)
    • Intrauterine hormone-releasing system (IUS)
    • Bilateral tubal occlusion
    • Vasectomised partner. Vasectomised partner is a highly effective birth control method provided that partner is the sole sexual partner of the WOCBP study participant and that the vasectomised partner has received medical assessment of the surgical success.
    • Sexual abstinence: abstinence is acceptable as a highly effective method of contraception only when it is consistent with the participant's usual and preferred lifestyle. Periodic or situational abstinence will not be considered acceptable for the purposes of meeting contraceptive requirements.

    Male participants should use a condom throughout the study. For a non-pregnant WOCBP partner, the highly effective contraception recommendations listed above should also be considered.

    Note: Birth control methods considered unacceptable in clinical trials Periodic abstinence (calendar, symptothermal, post-ovulation methods), withdrawal (coitus interruptus), spermicides only, and lactational amenorrhoea method (LAM) are not acceptable methods of contraception. Female condom and male condom should not be used together.

  5. Persistent pain for lasting > 3 months from the appearance of herpes zoster rash that is not located in proximity to mucous membranes.
  6. Diagnosis of PHN based on medical history as judged by investigator.
  7. Persistent neuropathic pain that involves at least one dermatome and covers ≤420 cm2.
  8. If the participant has been on stable dose(s) of oral analgesic medication(s) for at least 30 days prior to the Screening Visit, they need to be willing to maintain the respective dose(s) and medication throughout the study.
  9. Pain intensity score (NRS-11 score) in the target area of ≥ 5 at Screening Visit (Visit 1), and meeting all of the following conditions at Visit 2 (Day 1), prior to randomization:

    1. Baseline WAPS ≥5, as assessed using NRS-11 score in the target area. Participants with baseline WAPS \<5 will be considered screen failures.
    2. Participants who report an NRS-11 score \<5 on ≤ 1 occasion. Participants who report an NRS-11 score \<5 on ≥ 2 occasions within a week will be considered screen failures.
    3. Participants with evaluable WAPS, i.e., with WAPS records of ≥4 out of 7 data points collected during the Run-in period.

    Participants with WAPS records of \<4 out of 7 data points during the Run-in period will be considered screen failures.

  10. Skin is intact over the painful area to be treated.
  11. Able and willing to provide and comply with study procedures.
  12. In the opinion of the investigator, the PHN-affected area to be administered study drug will allow adequate contact of the study drug with the skin without affecting any mucous membranes.

Participants meeting ANY of the following exclusion criteria at the time of Screening will not be able to participate in this study.

Exclusion criteria

Exclusion criteria:

  1. Participant has systemic disease that would put him/her at an additional risk or limit his/her ability to participate in the study as judged by the investigator.
  2. Participant has a history of , , or .
  3. Participant has a history of other than basal cell carcinoma and carcinoma in situ within the past 2 years.
  4. Participant has a history of mental illness or psychiatric illness, such as dementia, depression, or schizophrenia, that can limit his/her ability to comply with study procedures as judged by the investigator.
  5. Participant is unable to apply, or to have a caregiver apply, the study spray to the most painful skin segments twice a day as directed.
  6. Participant has known sensitivity to lidocaine-containing products.
  7. Participant has active herpes zoster lesions or dermatitis.
  8. Participant has other condition(s) that cause severe or chronic pain that may impair the self-assessment of the pain due to PHN as judged by the investigator.
  9. Participant has been treated in the area of PHN with a local anesthetic within 14 days prior to Run-in period or has had a nerve block within 30 days prior to Run-in period.
  10. Participant is receiving or plans to receive any prohibited medication or therapy for the duration of the study, or is unable to washout these medications or therapies prior to Run-in period.
  11. Participant has used capsaicin patches within 90 days prior to Run-in period or has used other capsaicin preparations daily in the 90 days prior to Run-in period.
  12. Pregnant or lactating females.
  13. Participant has an active history of alcohol or drug abuse.
  14. Participant has participated in any other study within 30 days prior to Screening Visit.
  15. Participant or participant's direct family is employed by the sponsor or study staff.
  16. Participant has any condition that would make him/her unsuitable for the study in the opinion of the investigator or sponsor.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
333 participants (estimated)

Study arms

  • Experimental
    APC101

    Lidocaine spray 5% solution

    Drug: APC101

  • Placebo comparator
    Control

    Vehicle spray solution

    Other: Control

Interventions

  • DrugAPC101

    Lidocaine spray 5% solution

  • OtherControl

    A vehicle spray solution

06

What researchers measure

Primary outcomes

  1. NRS-11

    Change in the weekly average pain score\* (WAPS), assessed using NRS-11.

    Time frame: From baseline (Week -1; within 7 days ending on the date of randomization) to the evaluation conducted within 7 days ending on the date of the end of treatment (EOT).

07

Study locations

2 sites
  • Suncoast Clinical Research
    Florida City, Florida 34652, United States
  • University of Sunshine Cost
    Brisbane, Queensland 4117, Australia
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Aug 2026; primary completion for Dec 2028, 28 months later.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2026
First posted
May 20, 2026
StartEst.
Aug 1, 2026
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2029
Last update
May 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07599800
Lead sponsor
Andros Pharmaceuticals Co., Ltd.
Responsible party
Sponsor
First posted
May 20, 2026
Start date
Aug 1, 2026 (estimated)
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
May 20, 2026

Study contacts

Ae-June Wang, PhD
Contact
APC101_P3@andros.com.tw
+886-3-6581866

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion